摘要
目的:比较重组人促血小板生成素(rhTPO)与静脉注射丙种球蛋白(IVIG)联合糖皮质激素治疗初治重症原发免疫性血小板减少症(ITP)的有效性及安全性。方法:将66例初治重症ITP患者分为观察组(n=32)和对照组(n=34)。观察组采用rhTPO联合糖皮质激素治疗,对照组采用IVIG联合糖皮质激素治疗,比较两组治疗后血小板计数的变化、总反应率、起效及疗效维持时间、不良反应发生率。结果:治疗第15天,观察组中位血小板计数高于对照组(P=0.02),治疗第30天,观察组总有效率高于对照组(P=0.031);观察组起效时间长于对照组(P=0.001),但两组患者出血控制时间、疗效维持时间及不良反应发生率比较,差异无统计学意义(P>0.05)。结论:rhTPO联合激素可提高初治重症ITP患者的总有效率。
Objective:To compare the efficacy and safety of recombinant human thrombopoietin(rhTPO)and intravenous immunoglobulin(IVIG)combined with corticosteroids respectively in patients with initially treated severe primary immune thrombocytopenia(ITP).Methods:66 patients with initially treated severe ITP were randomly divided into two groups.The observation group(n=32)was treated with rhTPO combined with corticosteroids,and the control group(n=34)was treated with IVIG combined with corticosteroids.Changes in platelet counts after treatment,overall response rate,time to response,duration of response and adverse reaction rates were compared between the two groups after treatment.Results:After 15 days of treatment,the median platelet counts in the observation group was higher than that in the control group(P=0.02).After 30 days of treatment,overall response rate in the observation group was higher than that in the control group(P=0.031).The time to response in the observation group was longer than that in the control group(P=0.001),but there were no differences between these two groups in terms of the median bleeding control time,long-term response and incidence of adverse reactions(P>0.05).Conclusion:rhTPO combined corticosteroids can increase the overall response rate of patients with initially treated severe ITP.
作者
林晓静
邹兴立
赵小蓉
魏锦
LIN Xiao-jing;ZOU Xing-li;ZHAO Xiao-rong;WEI Jin(Department of Hematology,the Affiliated Hospital of North Sichuan Medical College,Nanchong 637000,Sichuan,China)
出处
《川北医学院学报》
CAS
2021年第2期159-162,共4页
Journal of North Sichuan Medical College
基金
四川省南充市市校科技战略合作项目(18SXHZ0136)。
关键词
原发免疫性血小板减少症
重症
RHTPO
IVIG
糖皮质激素
Primary immune thrombocytopenia(ITP)
Severe
Recombinant human thrombopoietin
Intravenous immunoglobulin
Corticosteroids
